What Are Biotechs Good At?
Biotech companies have seen themselves as proto-drug companies. But the real talents of many of them have little to do with becoming fully integrated discovery-based drug firms. They should be performing core-competency reviews to uncover their real distinctive talents, and then exploiting them--talents which may lie in dealmaking (e.g., only one of Chiron's three main products comes from its internal research), marketing (e.g., perhaps Genentech's best skill is differentiating its drugs from cheaper alternatives), clinical development, or even distribution (a la Axion).
You may also be interested in...
Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials
Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Some ACIP members argued woman older than 50 should also be singled out in warning for Johnson & Johnson’s COIVD-19 vaccine and said that people need to be more clearly told they can get alternative vaccines that don’t have this risk.